BDTX vs. AURA, TNYA, SLDB, OCGN, TRML, MGTX, JSPR, TCRX, CRBU, and REPL
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Aura Biosciences (AURA), Tenaya Therapeutics (TNYA), Solid Biosciences (SLDB), Ocugen (OCGN), Tourmaline Bio (TRML), MeiraGTx (MGTX), Jasper Therapeutics (JSPR), TScan Therapeutics (TCRX), Caribou Biosciences (CRBU), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Aura Biosciences (NASDAQ:AURA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.
Black Diamond Therapeutics received 27 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 63.93% of users gave Black Diamond Therapeutics an outperform vote while only 46.15% of users gave Aura Biosciences an outperform vote.
Black Diamond Therapeutics' return on equity of -41.79% beat Aura Biosciences' return on equity.
Aura Biosciences has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500.
Aura Biosciences currently has a consensus target price of $21.00, suggesting a potential upside of 188.86%. Black Diamond Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 146.41%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Black Diamond Therapeutics.
In the previous week, Black Diamond Therapeutics had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 15 mentions for Black Diamond Therapeutics and 3 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.12 beat Black Diamond Therapeutics' score of 0.64 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.
96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 5.9% of Aura Biosciences shares are held by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aura Biosciences is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
